







an Open Access Journal by MDPI

# **Quality of Life and Side Effects Management in Cancer Treatment**

Guest Editor:

### Prof. Dr. António Araújo

Centro Hospitalar Universitário de Santo António, Porto,
Portugal
Instituto de Ciências
Biomédicas Abel Salazar,
Universidade do Porto, Porto,
Portugal

Deadline for manuscript submissions:

closed (1 June 2023)

# **Message from the Guest Editor**

Dear Colleagues,

Cancer treatment has evolved in recent years in an unimaginable way, giving to our patients an increased rate of progression-free survival and/or overall survival. However, most importantly, these new drugs or new drug combinations are more patient friendly, increasing their quality of life. Nevertheless, we still have to learn how to control the adverse events involved in target therapy, immunotherapy and the new drugs of hormonotherapy.

We are, therefore, pleased to invite you to contribute to this Special Issue highlighting the current state of the art in the control of cancer treatments' adverse events and in improving the quality of care of cancer patients, as well as future prospects for improving therapies.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

## **Message from the Editor-in-Chief**

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

#### **Contact Us**